2-(1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid

Catalog No. :
ACRMAI318
CAS No. :
41340-25-4
Molecular Formula :
C17H21NO3
Molecular Weight :
287.36

IUPAC Name:2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid

2-(1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
25g99%$56.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name2-(1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid
IUPAC Name2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid
MDL No.MFCD00133313
Molecular FormulaC17H21NO3
Molecular Weight287.36
SMILESO=C(O)CC1(CC)OCCC2=C1NC3=C2C=CC=C3CC
InChI KeyNNYBQONXHNTVIJ-UHFFFAOYSA-N
SynonymEtodolac,(S) | Osteluc | Spectrum4_000410 | Etodolac (USAN:USP:INN:BAN) | Etodolac [USAN:USP:INN:BAN] | AY 24236 | Etogesic | EtodolacER | ETODOLAC [INN] | ETODOLAC [ORANGE BOOK] | Prestwick1_000231 | AY-24-236 | Flancox | etodolac o | Etodlic Acid | Etod
CAS No.41340-25-4
PubChem CID3308

Safety Data

Pictogram
Health hazardToxicHarmful or irritant
Signal Word
Danger
Hazard Statement(s)
H301-H319-H350-H360
Precautionary Statement(s)
P264-P270-P280-P301+P310+P330-P305+P351+P338-P337+P313-P405-P501

Synthetic Route by SureRoute

1. ACRMAI318 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACIRWK856 route compound structure diagram
    ACIRWK85658711-02-7 In Stock
  4. Then
  5. ACRMAI318 route product structure diagram
    ACRMAI31841340-25-4 In Stock
Inquiry

2. ACRMAI318 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACRMAI318 route product structure diagram
    ACRMAI31841340-25-4 In Stock
Inquiry

Comments (0)